Oura rings and GLP-1 fertility risks: what the science says

What did @drpoojagidwani actually say?

She said Ozempic can cause unplanned pregnancies through "hormonal changes" and by reducing the efficacy of birth control pills. She also said GLP-1 users should use backup contraception for the first four weeks of treatment and after each dose increase. Then she asked whether the Oura ring, recently cleared by the FDA alongside the Natural Cycles app for fertility tracking, could serve as that backup. Her answer was a clear no.

To her credit, she didn't hedge or bury the lead. She said directly: "We do not know anything about if Ozempic babies can be prevented with the Ora ring." She raised a specific biological concern, that GLP-1-related weight loss and calorie restriction can alter basal body temperature, which is the exact signal the Oura ring uses to estimate fertility windows. That's a reasonable mechanistic concern, even if no study has tested it yet.

Does the science back this up?

Mostly, yes. The link between GLP-1 agonists and unintended pregnancy is real, though the mechanism is still being worked out. The stronger evidence points to delayed gastric emptying reducing oral contraceptive absorption, not systemic hormonal changes per se.

The FDA-approved label for semaglutide (Ozempic, Wegovy) does recommend backup contraception for four weeks after initiation and after each dose escalation, which matches what she said. A 2023 letter in the New England Journal of Medicine (Johansson et al.) flagged a cluster of unintended pregnancies in women on semaglutide, largely attributed to reduced efficacy of oral contraceptives through slowed gastric emptying. There is no published research examining whether GLP-1 use alters basal body temperature independently of weight loss. Her concern is biologically plausible but currently unverifiable.

The FDA cleared the Oura ring with Natural Cycles in 2023 as a Class II medical device for fertility awareness. Cleared does not mean it performs comparably to hormonal contraception. Typical-use failure rates for fertility awareness methods remain higher than for IUDs or implants.

What did they get wrong (or right)?

She got the practical advice right. Backup contraception during GLP-1 initiation and dose increases is consistent with FDA labeling and current clinical guidance. Her recommendation against using the Oura ring as a contraceptive in this context is also sound, if slightly underexplained.

Where she was imprecise: calling the mechanism "hormonal changes" is a shortcut that muddles the actual pharmacology. The dominant explanation in the literature is pharmacokinetic, meaning the drug slows gastric emptying and reduces how much of an oral contraceptive gets absorbed, not that semaglutide directly alters reproductive hormones. That distinction matters for patients who use non-oral contraceptives like patches, rings, or IUDs, which would not be affected by gastric emptying. She did not address this, which could leave some viewers thinking any hormonal contraceptive is at risk.

She also said the Oura ring "was approved" for fertility tracking. It was cleared, not approved. These are different regulatory pathways with different evidentiary standards. Small point, but precision matters in contraception discussions.

What should you actually know?

If you are on a GLP-1 agonist and relying on oral contraceptives, you have a real pharmacokinetic problem worth discussing with your prescriber. The four-week backup recommendation is in the FDA labeling and is not controversial. Non-oral hormonal methods, like the patch, ring, injection, implant, or IUD, do not carry the same gastric absorption concern and are worth considering.

The Oura ring is a consumer wearable that received FDA clearance for use with one specific app under one specific protocol. It is not a contraceptive device. Its clearance was based on studies that did not include GLP-1 users, people with significant recent weight loss, or individuals with diet-related temperature variability. Using it as your primary or backup contraceptive while on Ozempic or any GLP-1 drug has no evidence base and carries meaningful risk.

• Speak with your prescriber before changing any contraceptive method while on a GLP-1 agonist.
• If you use oral contraceptives, ask whether a non-oral method is appropriate for you.
• Fertility awareness tools are not substitutes for medical contraception in high-stakes situations.